Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma
Metastatic disease from uveal melanoma occurs in almost 50% of patients suffering from this ocular tumour, with median survival from development of symptoms being around 1 year. In contrast to cutaneous melanoma, kinase inhibitors and immune checkpoint inhibitors are usually ineffective in patients...
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Journal article |
| Argitaratua: |
MDPI
2019
|